Mayo Clinic proceedings. Innovations, quality & outcomes最新文献

{"title":"Characteristics and Habits of Psychiatrists and Neurologists With High Occupational Well-Being: A Mixed Methods Study","authors":"Alexis Amano MS ,&nbsp;Nikitha K. Menon BS ,&nbsp;Stephanie Bissonnette DO, MPH ,&nbsp;Amy B. Sullivan PsyD, ABPP ,&nbsp;Natasha Frost MS, MD, FAAN ,&nbsp;Zariah Mekile MS, MAP ,&nbsp;Hanhan Wang MPS ,&nbsp;Tait D. Shanafelt MD, FACP ,&nbsp;Mickey T. Trockel MD, PhD","doi":"10.1016/j.mayocpiqo.2024.04.005","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.04.005","url":null,"abstract":"<div><h3>Objective</h3><p>To identify the characteristics that distinguish occupationally well outliers (OWO), a subset of academic psychiatrists and neurologists with consistently high professional fulfillment and low burnout, from their counterparts with lower levels of occupational well-being.</p></div><div><h3>Participants and Methods</h3><p>Participants included faculty physicians practicing psychiatry and neurology in academic medical centers affiliated with the Professional Well-being Academic Consortium. In this prospective, longitudinal study, a mixed qualitative and quantitative approach was used. Quantitative measures were administered to physicians in a longitudinal occupational well-being survey sponsored by the academic organizations where they work. Four organizations participated in the qualitative study. Psychiatrists and neurologists at these organizations who competed survey measures at 2 consecutive time points between 2019 and 2021 were invited to participate in an interview.</p></div><div><h3>Results</h3><p>Of 410 (213 psychiatrists and 197 neurologists) who completed professional fulfillment and burnout measures at 2 time points, 84 (20.5%) met OWO criteria. Occupationally well outliers psychiatrists and neurologists had more favorable scores on hypothesized determinants of well-being (values alignment, perceived gratitude, supportive leadership, peer support, and control of schedule). Ultimately, 31 psychiatrists (25% of 124 invited) and 33 neurologists (18.5% of 178 invited) agreed to participate in an interview. Qualitatively, OWO physicians differed from all others in 3 thematic domains: development of life grounded in priorities, ability to shape day-to-day work context, and professional relationships that provide joy and support.</p></div><div><h3>Conclusion</h3><p>A multilevel approach is necessary to promote optimal occupational well-being, targeting individual-level factors, organizational-level factors, and broader system-level factors.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000286/pdfft?md5=4481e6580d24833b009cc1ef6d1cef55&pid=1-s2.0-S2542454824000286-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141313536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rivaroxaban Versus Apixaban: A Comparison Without a Simple Solution","authors":"Marc Cohen MD ,&nbsp;Alex C. Spyropoulos MD ,&nbsp;Shaun G. Goodman MD ,&nbsp;Sarah A. Spinler PharmD ,&nbsp;Marc P. Bonaca MD ,&nbsp;Theresa M. Redling DO ,&nbsp;Gautam Visveswaran MD ,&nbsp;Sumit Sohal MD, MS","doi":"10.1016/j.mayocpiqo.2024.05.004","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.05.004","url":null,"abstract":"","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000328/pdfft?md5=3eef0453521a53f5d6c210e05ecc47aa&pid=1-s2.0-S2542454824000328-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141313538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the Prescribing of Buprenorphine for Opioid Use Disorder, 2019-2023","authors":"Samuel T. Savitz PhD ,&nbsp;Maria A. Stevens MA, MPH ,&nbsp;Bidisha Nath MBBS, MPH ,&nbsp;Gail D’Onofrio MD, MS ,&nbsp;Edward R. Melnick MD, MHS ,&nbsp;Molly M. Jeffery PhD","doi":"10.1016/j.mayocpiqo.2024.04.004","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.04.004","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate whether access to buprenorphine to treat opioid use disorder (OUD) was associated with the coronavirus disease pandemic, the relaxation of training requirements to obtain an X-Waiver to prescribe buprenorphine (April 2021), and the removal of the X-Waiver (December 2022).</p></div><div><h3>Patients and Methods</h3><p>The OptumLabs Data Warehouse, which includes claims from Commercial and Medicare Advantage enrollees, was used to evaluate trends in prescription fills from January 1, 2019, to June 30, 2023. We compared fill patterns of buprenorphine for OUD with acamprosate to treat alcohol use disorder and naltrexone to treat alcohol use disorder or OUD. We evaluated trends in the rate ratio (RR) of overall fills; RR by days supply; distribution of fills by daily dose; and distribution of fills by prescriber type.</p></div><div><h3>Results</h3><p>Coronavirus disease (RR, 1.06; 95% CI, 1.01-1.11) was associated with a slightly increased rate of fills for Commercial enrollees but not overall or for Medicare Advantage enrollees. There were also no significant increases (<em>P</em>&gt;0.05) associated with the change in training requirements or removal of the X-Waiver. Over the study period, there was an increasing share of fills for 16+ mg for Commercial enrollees, and buprenorphine prescribers were more likely to be advanced practice nurses or physician assistants.</p></div><div><h3>Conclusion</h3><p>We did not find meaningful improvement in access in response to coronavirus disease or the changes in the X-Waiver. These findings suggest that interventions beyond removing the X-Waiver may be needed to improve buprenorphine access.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000274/pdfft?md5=10e2289dd10b449327afd920248cbb8c&pid=1-s2.0-S2542454824000274-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity in Treatment Effect in Posttraumatic Stress Syndrome Trials: A Meta-Regression Analysis","authors":"Sammy T. Murad ,&nbsp;Allison L. Hansen ,&nbsp;Leslie A. Sim PhD, LP ,&nbsp;M. Hassan Murad MD, MPH","doi":"10.1016/j.mayocpiqo.2024.04.003","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.04.003","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the heterogeneity in treatment effect in posttraumatic stress disorder (PTSD) trials.</p></div><div><h3>Patients and Methods</h3><p>We downloaded data from a publicly available repository that captured PTSD trials published from January 1988 through February 2023. We applied restricted maximum-likelihood random-effect meta-analyses and meta-regression to explore potential moderators of treatment effect including methodologic study features (risk of bias domains and control group response rate), characteristics of the population, and intervention features following the theme, intensity, and platform framework.</p></div><div><h3>Results</h3><p>We included 199 PTSD trials that reported the outcomes of diagnosis resolution (122 trials, 8437 patients) and clinically meaningful improvement (133 trials, 9895 patients). Multiple treatments demonstrated effectiveness but with significant heterogeneity. Statistically significant moderators included risk of bias domains of randomization sequence and outcome measurement, control group response rate reflecting severity of PTSD in the enrolled population, and whether the psychotherapeutic approach was trauma focused (<em>P</em> values &lt;0.05). There was no statistically significant effect for the frequency of treatments per week, format of the intervention (eg, individual vs group), duration of the intervention, or delivery method (in person vs not), (<em>P</em> values &lt;0.05). Characteristics of the population such as sex, age, and military status did not appear to significantly affect the treatment effect (<em>P</em> values &lt;0.05).</p></div><div><h3>Conclusion</h3><p>Trauma focused psychotherapies should be considered the first-line intervention to induce remission. Several patient characteristics or treatment context did not modify the treatment effect, which allows tailoring care based on patient values, preferences and logistics.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000262/pdfft?md5=9eaaba7ab0feb6859af462289f6e8379&pid=1-s2.0-S2542454824000262-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141091054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Intravenous and Subcutaneous Insulin Overlap During Treatment of Diabetic Ketoacidosis: A Quality Improvement Project","authors":"Andrew A. Welch DO ,&nbsp;David Toro-Tobon MD ,&nbsp;Kharisa N. Rachmasari MD ,&nbsp;Rashi B. Sandooja MBBS ,&nbsp;Leili Rahimi MD ,&nbsp;Sneha Mohan MBBS ,&nbsp;Jennifer R. Hewlett MD ,&nbsp;Jennifer Clark MD ,&nbsp;Arvind Maheshwari MD ,&nbsp;Catherine Zhang MD ,&nbsp;Juan P. Brito MD","doi":"10.1016/j.mayocpiqo.2024.03.008","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.03.008","url":null,"abstract":"<div><h3>Objective</h3><p>To reduce the frequency of insufficient overlap of intravenous (IV) and subcutaneous (SC) insulin during the treatment of diabetic ketoacidosis (DKA) as a quality improvement project.</p></div><div><h3>Patients and Methods</h3><p>Rates of insufficient IV and SC insulin overlap (&lt; 2-hour overlap, SC insulin given after IV insulin discontinuation, or no SC insulin given after IV insulin discontinuation) were assessed in adults with DKA treated with IV insulin at a large tertiary care referral center in Rochester, Minnesota, from July 1, 2021, to March 15, 2023. After a preintervention analysis period, an electronic medical record–based best practice advisory was introduced to notify hospital providers discontinuing IV insulin if SC long-acting insulin had not been given in the previous 2-6 hours. Demographic characteristics and clinical outcomes before and after intervention were compared.</p></div><div><h3>Results</h3><p>A total of 352 patient encounters were included (251 in the preintervention phase and 101 in the postintervention phase). The rate of insufficient IV to SC insulin overlap decreased from (88 of 251) 35.1% before intervention to (20 of 101) 19.8% after intervention (<em>P</em>=.005). The rate of posttransition hypoglycemia (&lt;70 mg/dL; to convert to mmol/L, multiply by 0.0259) decreased from (27 of 251) 10.7% to (4 of 101) 4% after intervention (<em>P</em>=.04). Rates of posttransition hyperglycemia (&gt;250 mg/dL), rebound DKA, length of hospital stay, and duration of IV insulin therapy were similar before and after intervention.</p></div><div><h3>Conclusion</h3><p>Using quality improvement methodology, the rates of insufficient IV to SC insulin overlap during treatment of DKA in a large tertiary care referral center were measured and reduced through an electronic medical record–based best practice advisory targeting hospital providers.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000237/pdfft?md5=18b5044057996369c6c3a9a2e0bdac68&pid=1-s2.0-S2542454824000237-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141078062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Lifestyle Medicine in New York City’s Public Health Care System","authors":"John S. Babich BS ,&nbsp;Michelle McMacken MD ,&nbsp;Lilian Correa MA, MPH, RDN ,&nbsp;Krisann Polito-Moller BS, NBC-HWC ,&nbsp;Kevin Chen MD, MHS ,&nbsp;Eric Adams MPA ,&nbsp;Samantha Morgenstern MS, RD, CDN ,&nbsp;Mitchell Katz MD ,&nbsp;Theodore G. Long MD, MHS ,&nbsp;Shivam Joshi MD ,&nbsp;Andrew B. Wallach MD ,&nbsp;Sapana Shah MD, MPH ,&nbsp;Rebecca Boas MD, MBA","doi":"10.1016/j.mayocpiqo.2024.01.005","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.01.005","url":null,"abstract":"<div><p>Chronic diseases are the leading cause of death and disability in the United States, and much of this burden can be attributed to lifestyle and behavioral risk factors. Lifestyle medicine is an approach to preventing and treating lifestyle-related chronic disease using evidence-based lifestyle modification as a primary modality. NYC Health + Hospitals, the largest municipal public health care system in the United States, is a national pioneer in incorporating lifestyle medicine systemwide. In 2019, a pilot lifestyle medicine program was launched at NYC Health + Hospitals/Bellevue to improve cardiometabolic health in high-risk patients through intensive support for evidence-based lifestyle changes. Analyses of program data collected from January 29, 2019 to February 26, 2020 demonstrated feasibility, high demand for services, high patient satisfaction, and clinically and statistically significant improvements in cardiometabolic risk factors. This pilot is being expanded to 6 new NYC Health + Hospitals sites spanning all 5 NYC boroughs. As part of the expansion, many changes have been implemented to enhance the original pilot model, scale services effectively, and generate more interest and incentives in lifestyle medicine for staff and patients across the health care system, including a plant-based default meal program for inpatients. This narrative review describes the pilot model and outcomes, the expansion process, and lessons learned to serve as a guide for other health systems.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000201/pdfft?md5=a86ed4db89fa2cfcb4f41c6f57148900&pid=1-s2.0-S2542454824000201-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141078745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Severe Ischemic Left Ventricular Systolic Dysfunction","authors":"Ruth A. Mathew Kalathil MD ,&nbsp;Akshay Machanahalli Balakrishna MD ,&nbsp;Ahmed El-Shaer MD ,&nbsp;Andrew M. Goldsweig MD, MS ,&nbsp;Khagendra Dahal MD ,&nbsp;Saraschandra Vallabhajosyula MD, MSc ,&nbsp;Ahmed Aboeata MD","doi":"10.1016/j.mayocpiqo.2024.04.002","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.04.002","url":null,"abstract":"<div><p>Coronary artery disease is the most common cause of heart failure, which is the leading cause of cardiovascular-related death worldwide. There are insufficient data to make strong recommendations for percutaneous coronary intervention (PCI) in patients with severe ischemic left ventricular systolic dysfunction (LVSD). In that context, we performed a meta-analysis to compare the outcomes of PCI with those of optimal medical therapy alone in patients with severe ischemic LVSD. A systematic search was conducted in PubMed, EMBASE, and <span>ClinicalTrials.gov</span><svg><path></path></svg> from inception to December 2023. Our outcome of interest was all-cause mortality in patients undergoing PCI vs medical therapy. We used random effects models to aggregate data and to calculate pooled incidence and relative risk with 95% CIs. Four studies including 2 randomized controlled trials with 2080 patients (PCI, 1082; optimal medical therapy, 998) were included. All-cause mortality did not differ significantly between the groups: 168 patients (15.5%) in the PCI group vs 200 patients (20.0%) in the optimal medical therapy group (relative risk, 0.88; 95% CI, 0.75-1.09; <em>P</em>=.25). In conclusion, the available evidence indicates that PCI does not improve all-cause mortality in patients with severe LVSD without lifestyle-limiting anginal symptoms. Further data are needed to identify subgroups of patients better served by each modality.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000250/pdfft?md5=7fe4927a10a4fe4f8a0c1dbe0c0317dd&pid=1-s2.0-S2542454824000250-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141068240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supporting Sustainable Health Behavior Change: The Whole is Greater Than the Sum of Its Parts","authors":"Jessica A. Matthews DBH, NBC-HWC, DipACLM, FACLM ,&nbsp;Simon Matthews MHlthSc, NBC-HWC, PCC, DipIBLM, FASLM ,&nbsp;Mark D. Faries PhD ,&nbsp;Ruth Q. Wolever PhD, NBC-HWC","doi":"10.1016/j.mayocpiqo.2023.10.002","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2023.10.002","url":null,"abstract":"<div><p>Behavior change is the foundation for effective lifestyle prescriptions, yet such change is individualized, nonlinear and typically requires ongoing support. Health and wellness coaching (HWC) is a behavior change intervention with rapidly accruing evidence of positive impact on health behaviors such as exercise, nutrition and stress management. Furthermore, HWC enhances prevention and mitigates exacerbation of chronic lifestyle diseases, at least in the short-term (up to 6 months post intervention). Although the impact on long-term stability of behavior change remains unclear, it is evident that effective partnering with patients using key communication strategies, autonomy promotion, and flexible permissiveness can empower patients to develop healthy lifestyles. This partnership can be cultivated by clinicians as well as clinical team members including nationally board-certified coaches. Although much research is needed regarding the ongoing maintenance of lifestyle changes beyond 6 months, this article seeks to equip clinicians with current evidence, theoretical insights and practical strategies from a “coach approach” to foster more intrinsic forms of motivation which, in turn, empowers patients to adopt and maintain health-promoting behaviors.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000225/pdfft?md5=070b9e0b12433a14fa5430cd746b3a71&pid=1-s2.0-S2542454824000225-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141068242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic Clusters and Multimorbidity in Hypermobile Ehlers-Danlos Syndrome","authors":"Taylor Petrucci BS ,&nbsp;S. Jade Barclay MPH ,&nbsp;Cortney Gensemer PhD ,&nbsp;Jordan Morningstar BS ,&nbsp;Victoria Daylor BFA ,&nbsp;Kathryn Byerly BS ,&nbsp;Erika Bistran BS ,&nbsp;Molly Griggs MEd ,&nbsp;James M. Elliot PhD ,&nbsp;Teresa Kelechi RN, PhD ,&nbsp;Shannon Phillips RN, PhD ,&nbsp;Michelle Nichols RN, PhD ,&nbsp;Steven Shapiro DMD, MD ,&nbsp;Sunil Patel MD ,&nbsp;Nabila Bouatia-Naji PhD ,&nbsp;Russell A. Norris PhD","doi":"10.1016/j.mayocpiqo.2024.04.001","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.04.001","url":null,"abstract":"<div><h3>Objective</h3><p>To perform a retrospective clinical study in order to investigate phenotypic penetrance within a large registry of patients with hypermobile Ehlers-Danlos syndrome (hEDS) to enhance diagnostic and treatment guidelines by understanding associated comorbidities and improving accuracy in diagnosis.</p></div><div><h3>Patients and Methods</h3><p>From May 1, 2021 to July 31, 2023, 2149 clinically diagnosed patients with hEDS completed a self-reported survey focusing on diagnostic and comorbid conditions prevalence. K-means clustering was applied to analyze survey responses, which were then compared across gender groups to identify variations and gain clinical insights.</p></div><div><h3>Results</h3><p>Analysis of clinical manifestations in this cross-sectional cohort revealed insights into multimorbidity patterns across organ systems, identifying 3 distinct patient groups. Differences among these phenotypic clusters provided insights into diversity within the population with hEDS and indicated that Beighton scores are unreliable for multimorbidity phenotyping.</p></div><div><h3>Conclusion</h3><p>Clinical data on the phenotypic presentation and prevalence of comorbidities in patients with hEDS have historically been limited. This study provides comprehensive data sets on phenotypic presentation and comorbidity prevalence in patients with hEDS, highlighting factors often overlooked in diagnosis. The identification of distinct patient groups emphasizes variations in hEDS manifestations beyond current guidelines and emphasizes the necessity of comprehensive multidisciplinary care for those with hEDS.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000249/pdfft?md5=173024d0e7b069283554ef79152bdff4&pid=1-s2.0-S2542454824000249-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic-Assisted Resection of Rare Mitral Valve Hemangioma","authors":"Raffaele Rocco MD,&nbsp;Richard Daly MD,&nbsp;Armin Arghami MD","doi":"10.1016/j.mayocpiqo.2024.03.007","DOIUrl":"https://doi.org/10.1016/j.mayocpiqo.2024.03.007","url":null,"abstract":"<div><p>Cardiac hemangiomas are extremely rare tumors accounting for only 1.5%-2.5% of all cardiac tumors. According to most recent literature, only 13 mitral valve hemangiomas have been reported. A 78-year-old man was undergoing routine transthoracic echocardiography monitoring for an ascending aortic dilation when a vegetation on the mitral leaflet was incidentally detected. This lesion presented as a 0.5- × 0.6-cm mobile mass arising from the medial aspect of the A2 cusp. Despite the asymptomatic nature of the aforementioned lesion, resection was pursued given presumed diagnosis of papillary fibroelastoma and concern for risk of stroke. The mass was resected using minimally invasive robotic approach, and final pathology was consistent with hemangioma.</p></div>","PeriodicalId":94132,"journal":{"name":"Mayo Clinic proceedings. Innovations, quality & outcomes","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542454824000213/pdfft?md5=08b94c39e8745d053e31c79dd69d294d&pid=1-s2.0-S2542454824000213-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140893915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}